(Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner ...
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss ...
Allurion, while battling declining revenues, is targeting the loss in muscle mass seen in patients on GLP-1RA therapy.
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...
NextEra Energy stock was rising Friday, although the renewable-energy company’s revenue for the fourth quarter fell short of ...
Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an ...
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
Wells Fargo (WFC), Goldman Sachs (GS), Citigroup (C), Bank of America (BAC), and Morgan Stanley (MS) all beat estimates, instilling confidence that the Financials sector earned its 28% performance ...
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...
When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...
We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...